Odevixibat reduces markers of progressive familial intrahepatic cholestasis in children

Odevixibat reduces markers of progressive familial intrahepatic cholestasis in children

Odevixibat treatment reduced levels of peripheral blood autotaxin, pruritus and serum bile acid among pediatric patients with progressive familial intrahepatic cholestasis, according to pooled data.“Progressive familial intrahepatic cholestasis, or PFIC, is a group of rare genetic liver diseases characterized by chronic cholestasis, high serum bile acids and severe pruritis being the hallmarks of the disease and progressive liver disease. Lysophosphatidic acid mainly produced by autotaxin and serum bile acids are both possible pruritic mediators,” Emmanuel Gonzales, MD, PhD, ofRead More

Share on facebook
Share on twitter
Share on linkedin